Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program

Myron J. Levin, Jennifer Duchon, Geeta K. Swamy, Anne A. Gershon

PLoS ONE · 2019 · 52 citations · 34 references

DOIFull text

Open access

Abstract

Postexposure administration of VARIZIG was associated with low rates of varicella in high-risk participants, regardless of when administered within 10 days postexposure. VARIZIG was well-tolerated and safe in high-risk participants.

References

34